報價延遲最少15分鐘:2024/06/14 17:36 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3327 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.65/-1.03
|
|
企業價值
2.29M
|
| 資產負債 |
|
每股賬面淨值
2.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/14 17:36 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIaclinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |